Two phase 2 trials with different selective TYK2 inhibitors produce high rates of efficacy in moderate to severe plaque ...

High Psoriasis Response With New TYK2 Inhibitor Three-fourths of patients ... Currently approved therapies for alopecia areata are all JAK inhibitors and carry boxed warning labels, King noted.

Tyrosine kinase 2 (TYK2) is a member of the JAK kinase family of intracellular signaling molecules. By participating in signaling pathways downstream of type I interferons, IL-12, IL-23 and IL-10 ...

There are already several JAK inhibitors on the market – including Pfizer's own Xeljanz (abrocitinib) – while the TYK2 category is being led by Bristol-Myers Squibb's deucravacitinib ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ORLANDO -- The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis ...

“TYK2 offers the potential to target IL-23 ... However, all first-generation JAK inhibitors designed to target the enzyme family’s kinase domain exhibited some degree of cross-reactivity ...

Dr Strowd also discusses a 12-week phase 2 dose-ranging study of an oral JAK1/TYK2 inhibitor, which showed that 80% of the patients receiving 10 mg and 20 mg twice daily achieved an EASI-75 ...

Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 (TYK2) inhibitor as a dermatology treatment in Japan. The drug in ...

SOUTH SAN FRANCISCO, Calif., March 25, 2025--(BUSINESS WIRE)--Neuron23 ® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined ...

next-generation oral tyrosine kinase 2 (TYK2) inhibitor, for dermatology indications in Japan, with the option to expand the license to include rheumatological and gastrointestinal diseases.